Molecular Templates Past Earnings Performance
Past criteria checks 0/6
Molecular Templates has been growing earnings at an average annual rate of 15.8%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 17.2% per year.
Key information
15.8%
Earnings growth rate
24.0%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 17.2% |
| Return on equity | -219.7% |
| Net Margin | -61.4% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
There's No Escaping Molecular Templates, Inc.'s (NASDAQ:MTEM) Muted Revenues Despite A 30% Share Price Rise
Oct 10
Earnings Release: Here's Why Analysts Cut Their Molecular Templates, Inc. (NASDAQ:MTEM) Price Target To US$18.00
Aug 17Molecular Templates, Inc.'s (NASDAQ:MTEM) Shares Bounce 27% But Its Business Still Trails The Industry
Jul 30Little Excitement Around Molecular Templates, Inc.'s (NASDAQ:MTEM) Revenues As Shares Take 48% Pounding
Apr 03Lacklustre Performance Is Driving Molecular Templates, Inc.'s (NASDAQ:MTEM) 26% Price Drop
Dec 20There's No Escaping Molecular Templates, Inc.'s (NASDAQ:MTEM) Muted Revenues Despite A 45% Share Price Rise
Apr 17What Does The Future Hold For Molecular Templates, Inc. (NASDAQ:MTEM)? These Analysts Have Been Cutting Their Estimates
Nov 16Time To Worry? Analysts Are Downgrading Their Molecular Templates, Inc. (NASDAQ:MTEM) Outlook
Aug 14Molecular Templates GAAP EPS of -$0.44 misses by $0.01, revenue of $4.42M misses by $2.6M
Aug 11Rock star Growth Puts Molecular Templates (NASDAQ:MTEM) In A Position To Use Debt
Apr 29Health Check: How Prudently Does Molecular Templates (NASDAQ:MTEM) Use Debt?
Dec 30Some Analysts Just Cut Their Molecular Templates, Inc. (NASDAQ:MTEM) Estimates
Nov 25Is Molecular Templates (NASDAQ:MTEM) Using Debt In A Risky Way?
Sep 22News Flash: Analysts Just Made A Notable Upgrade To Their Molecular Templates, Inc. (NASDAQ:MTEM) Forecasts
Aug 15Need To Know: Analysts Just Made A Substantial Cut To Their Molecular Templates, Inc. (NASDAQ:MTEM) Estimates
May 18Brokers Are Upgrading Their Views On Molecular Templates, Inc. (NASDAQ:MTEM) With These New Forecasts
Mar 21Need To Know: The Consensus Just Cut Its Molecular Templates, Inc. (NASDAQ:MTEM) Estimates For 2021
Feb 21Is Molecular Templates (NASDAQ:MTEM) A Risky Investment?
Jan 26
Revenue & Expenses Breakdown
How Molecular Templates makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 25 | -16 | 15 | 0 |
| 31 Mar 24 | 32 | -18 | 17 | 0 |
| 31 Dec 23 | 57 | -8 | 19 | 0 |
| 30 Sep 23 | 53 | -26 | 21 | 0 |
| 30 Jun 23 | 50 | -47 | 23 | 0 |
| 31 Mar 23 | 48 | -60 | 24 | 0 |
| 31 Dec 22 | 20 | -93 | 26 | 0 |
| 30 Sep 22 | 35 | -81 | 27 | 0 |
| 30 Jun 22 | 33 | -87 | 31 | 0 |
| 31 Mar 22 | 44 | -78 | 33 | 0 |
| 31 Dec 21 | 39 | -83 | 34 | 0 |
| 30 Sep 21 | 24 | -101 | 33 | 0 |
| 30 Jun 21 | 26 | -94 | 32 | 0 |
| 31 Mar 21 | 18 | -110 | 29 | 0 |
| 31 Dec 20 | 19 | -105 | 27 | 0 |
| 30 Sep 20 | 22 | -92 | 26 | 0 |
| 30 Jun 20 | 21 | -107 | 23 | 0 |
| 31 Mar 20 | 19 | -85 | 21 | 0 |
| 31 Dec 19 | 22 | -69 | 20 | 0 |
| 30 Sep 19 | 21 | -60 | 18 | 0 |
| 30 Jun 19 | 24 | -27 | 17 | 0 |
| 31 Mar 19 | 20 | -28 | 16 | 0 |
| 31 Dec 18 | 13 | -30 | 14 | 0 |
| 30 Sep 18 | 9 | -31 | 14 | 0 |
| 30 Jun 18 | 3 | -36 | 12 | 0 |
| 31 Mar 18 | 2 | -31 | 11 | 0 |
| 31 Dec 17 | 3 | -24 | 10 | 0 |
| 30 Sep 17 | 3 | -20 | 8 | 0 |
| 30 Jun 17 | 2 | -13 | 6 | 0 |
| 31 Mar 17 | 3 | -11 | 5 | 0 |
| 31 Dec 16 | 2 | -13 | 4 | 0 |
| 31 Dec 15 | 1 | -7 | 3 | 0 |
Quality Earnings: MTEM is currently unprofitable.
Growing Profit Margin: MTEM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MTEM is unprofitable, but has reduced losses over the past 5 years at a rate of 15.8% per year.
Accelerating Growth: Unable to compare MTEM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MTEM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: MTEM has a negative Return on Equity (-219.74%), as it is currently unprofitable.